Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.

Front Psychiatry · 2018 · PMC5893641 · PMID 29670547

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a trend toward significanceno p-value reported

Patients who received final doses of lurasidone 120 and 160 mg daily showed significantly greater improvement in the overall cognitive performance compared to that with quetiapine XR at 6 months, while 40 and 80 mg daily treatment showed a trend toward significance at 6 months ( 65 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.